BioTime Company Profile (NYSEMKT:BTX)

About BioTime (NYSEMKT:BTX)

BioTime logoBioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NYSEMKT:BTX
  • CUSIP: 09066L10
  • Web: N/A
Capitalization:
  • Market Cap: $362.56 million
  • Outstanding Shares: 110,875,000
Average Prices:
  • 50 Day Moving Avg: $3.23
  • 200 Day Moving Avg: $3.32
  • 52 Week Range: $2.26 - $4.01
P/E:
  • Trailing P/E Ratio: 3.38
  • Foreward P/E Ratio: -8.84
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.24 million
  • Price / Sales: 85.51
  • Book Value: $1.69 per share
  • Price / Book: 1.93
Profitability:
  • EBIDTA: ($42,640,000.00)
Misc:
  • Average Volume: 345,115 shs.
  • Beta: 1.37
  • Short Ratio: 9.72
 

Frequently Asked Questions for BioTime (NYSEMKT:BTX)

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEMKT:BTX) released its earnings results on Tuesday, August, 9th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.06. The business had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.75 million. View BioTime's Earnings History.

Where is BioTime's stock going? Where will BioTime's stock price be in 2017?

2 brokerages have issued 12-month target prices for BioTime's shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate BioTime's stock price to reach $6.00 in the next year. View Analyst Ratings for BioTime.

Who are some of BioTime's key competitors?

Who owns BioTime stock?

BioTime's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.06%), Geode Capital Management LLC (1.02%), Destination Wealth Management (0.58%), Bank of New York Mellon Corp (0.43%), Family Management Corp (0.13%) and Teachers Advisors LLC (0.12%). Company insiders that own BioTime stock include Alfred D Kingsley, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Stephen C Farrell and Stephen Lahue Cartt. View Institutional Ownership Trends for BioTime.

Who sold BioTime stock? Who is selling BioTime stock?

BioTime's stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Granite Point Capital Management L.P. and California Public Employees Retirement System. View Insider Buying and Selling for BioTime.

Who bought BioTime stock? Who is buying BioTime stock?

BioTime's stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Vanguard Group Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., Russell Investments Group Ltd., KCG Holdings Inc., Bank of New York Mellon Corp and Nine Chapters Capital Management LLC. Company insiders that have bought BioTime stock in the last two years include Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Stephen C Farrell and Stephen Lahue Cartt. View Insider Buying and Selling for BioTime.

How do I buy BioTime stock?

Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioTime stock cost?

One share of BioTime stock can currently be purchased for approximately $3.27.

Analyst Ratings

Consensus Ratings for BioTime (NYSEMKT:BTX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00

Analysts' Ratings History for BioTime (NYSEMKT:BTX)
Show:
DateFirmActionRatingPrice TargetDetails
3/31/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$6.00View Rating Details
9/23/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$6.00View Rating Details
4/7/2016Chardan CapitalInitiated CoverageBuyView Rating Details
4/2/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for BioTime (NYSEMKT:BTX)
Earnings by Quarter for BioTime (NYSEMKT:BTX)
Earnings History by Quarter for BioTime (NYSEMKT:BTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016Q316($0.14)($0.08)$1.46 million$1.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.17)($0.11)$1.75 million$1.27 millionViewN/AView Earnings Details
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
3/15/2016Q4($0.17)($0.16)$1.31 millionViewN/AView Earnings Details
8/10/2015Q2($0.12)$2.01 millionViewN/AView Earnings Details
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)$0.61 million$1.07 millionViewN/AView Earnings Details
11/12/2013Q3($0.16)ViewN/AView Earnings Details
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioTime (NYSEMKT:BTX)
Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS

Dividends

Dividend History for BioTime (NYSEMKT:BTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioTime (NYSEMKT:BTX)
Insider Trades by Quarter for BioTime (NYSEMKT:BTX)
Institutional Ownership by Quarter for BioTime (NYSEMKT:BTX)
Insider Trades by Quarter for BioTime (NYSEMKT:BTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Deborah J AndrewsDirectorBuy2,000$3.21$6,420.00View SEC Filing  
2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.00View SEC Filing  
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.00View SEC Filing  
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.00View SEC Filing  
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioTime (NYSEMKT:BTX)
Latest Headlines for BioTime (NYSEMKT:BTX)
Source:
DateHeadline
finance.yahoo.com logoBioTime, Inc. breached its 200 day moving average in a Bullish Manner : BTX-US : May 25, 2017
finance.yahoo.com - May 25 at 5:38 AM
businesswire.com logoBioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) - Business Wire (press release)
www.businesswire.com - May 25 at 12:37 AM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Idera Pharma, BioTime, RXi Pharma, and Tenax Therapeutics - PR Newswire (press release)
www.prnewswire.com - May 24 at 10:48 AM
finance.yahoo.com logoBioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
finance.yahoo.com - May 23 at 6:03 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 23 at 4:24 PM
businesswire.com logoBioTime Presents Retinal Restoration Data at ARVO | Business Wire - Business Wire (press release)
www.businesswire.com - May 11 at 9:42 PM
streetinsider.com logoBioTime (BTX) Reports New Data from OpRegen Trial in Dry-AMD at ARVO Meeting
www.streetinsider.com - May 11 at 4:40 PM
finance.yahoo.com logoEndocyte (ECYT) Reports Narrower-than-Expected Loss in Q1
finance.yahoo.com - May 11 at 4:40 PM
finance.yahoo.com logoValeant (VRX) Q1 Earnings & Revenues Miss, View Raised
finance.yahoo.com - May 11 at 2:17 AM
finance.yahoo.com logoBioTime posts 1Q profit
finance.yahoo.com - May 10 at 9:17 PM
finance.yahoo.com logoProthena (PRTA) Q1 Loss Narrower than Expected, Updates View
finance.yahoo.com - May 10 at 4:16 PM
businesswire.com logoBioTime Co-CEO Dr. Michael D. West to Present at World Advanced ... - Business Wire (press release)
www.businesswire.com - May 9 at 8:33 AM
streetinsider.com logoBioTime (BTX) Reports New Data from OpRegen Trial in Dry-AMD at ARVO Meeting - StreetInsider.com
www.streetinsider.com - May 9 at 8:33 AM
finance.yahoo.com logoBioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
finance.yahoo.com - May 9 at 8:33 AM
finance.yahoo.com logoBioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
finance.yahoo.com - May 8 at 10:19 AM
americanbankingnews.com logoBioTime, Inc. (BTX) to Release Earnings on Wednesday
www.americanbankingnews.com - May 8 at 8:52 AM
finance.yahoo.com logoBioTime, Inc. is trading below its 50 day moving average : BTX-US : May 5, 2017
finance.yahoo.com - May 5 at 4:09 PM
americanbankingnews.com logoBioTime (BTX) Earning Favorable Media Coverage, Report Finds
www.americanbankingnews.com - May 3 at 12:48 AM
finance.yahoo.com logoBioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : May 2, 2017
finance.yahoo.com - May 2 at 7:53 PM
americanbankingnews.com logoBioTime (BTX) Receiving Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 29 at 5:27 PM
finance.yahoo.com logoBioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
finance.yahoo.com - April 26 at 8:32 AM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Likely to Affect BioTime (BTX) Stock Price
www.americanbankingnews.com - April 25 at 3:55 PM
finance.yahoo.com logoBioTime to Present Additional Data at Upcoming ARVO - Yahoo Finance
finance.yahoo.com - April 25 at 3:31 PM
finance.yahoo.com logoBioTime to Present Additional Data at Upcoming ARVO
finance.yahoo.com - April 24 at 9:55 AM
finance.yahoo.com logoBioTime, Inc. is trading below its 50 day moving average : BTX-US : April 21, 2017
finance.yahoo.com - April 21 at 6:33 AM
finance.yahoo.com logoBioTime, Inc. – Value Analysis (NYSE MKT:BTX) : April 20, 2017
finance.yahoo.com - April 20 at 4:12 PM
finance.yahoo.com logoBioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : April 19, 2017
finance.yahoo.com - April 19 at 1:06 PM
americanbankingnews.com logoBioTime (BTX) Given Daily News Impact Rating of 0.28
www.americanbankingnews.com - April 17 at 9:36 AM
americanbankingnews.com logoBioTime (BTX) Earns Media Sentiment Rating of 0.57
www.americanbankingnews.com - April 14 at 8:24 AM
finance.yahoo.com logoETFs with exposure to BioTime, Inc. : April 13, 2017
finance.yahoo.com - April 13 at 4:12 PM
businesswire.com logoBioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging - Business Wire (press release)
www.businesswire.com - April 7 at 8:43 AM
finance.yahoo.com logoBioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
finance.yahoo.com - April 7 at 8:43 AM
finance.yahoo.com logoBioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging
finance.yahoo.com - April 7 at 8:43 AM
finance.yahoo.com logoCoverage initiated on BioTime by Raymond James
finance.yahoo.com - March 31 at 9:15 PM
americanbankingnews.com logoRaymond James Financial, Inc. Initiates Coverage on BioTime, Inc. (BTX)
www.americanbankingnews.com - March 31 at 12:02 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 7:23 AM
streetinsider.com logoBioTime (BTX) Announces Key Patents Upheld by European Patent Office
www.streetinsider.com - March 28 at 12:58 PM
biz.yahoo.com logoBIOTIME INC Files SEC form 8-K, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 28 at 12:58 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 24 at 7:22 PM
finance.yahoo.com logoBIOTIME INC Financials
finance.yahoo.com - March 23 at 4:30 PM
finance.yahoo.com logoBioTime to Present at Oppenheimer 27th Annual Healthcare ... - Yahoo Finance
finance.yahoo.com - March 20 at 12:58 PM
nasdaq.com logoAVXS Abuzz, PTCT Slammed For Emflaza Deal, INNL Scouts For Buyer
www.nasdaq.com - March 17 at 2:39 AM
biz.yahoo.com logoQ4 2016 BioTime Inc Earnings Release - After Market Close
biz.yahoo.com - March 16 at 4:35 PM
finance.yahoo.com logoData From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
finance.yahoo.com - March 15 at 4:26 PM
businesswire.com logoClinical Trial in Dry-AMD With Opening of First US Sites - Business Wire (press release)
www.businesswire.com - March 13 at 4:14 PM
finance.yahoo.com logoBioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
finance.yahoo.com - March 13 at 12:54 PM
seekingalpha.com logoBioTime: 3-D Retinal Tissue Licensing Agreement
seekingalpha.com - February 23 at 9:03 PM
finance.yahoo.com logoBioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
finance.yahoo.com - February 23 at 4:02 PM
investopedia.com logoBioTime Reports $56M Non-Cash Gain (BTX,OCX) - Investopedia
www.investopedia.com - February 22 at 9:10 PM
nasdaq.com logoBioTime (BTX) Shows Strength: Stock Adds 7.1% in Session - Nasdaq
www.nasdaq.com - February 22 at 9:10 PM

Social

This page was last updated on 5/25/2017 by MarketBeat.com Staff